Towa Pharmaceutical Co., Ltd.

Sunsho Pharmaceutical Co., Ltd. (HQ: Fuji City, Shizuoka Prefecture; CEO: Row Imamura), a leader in capsule development and manufacturing, is pleased to announce the successful completion of its acquisition of “Kamata Co., Ltd.” (HQ: Tokyo; CEO: Izumi Kamata), a prominent health food contract manufacturer specializing in soft capsules. Initially announced on December 11, 2023, Sunsho Pharmaceutical Co., Ltd. finalized the acquisition of Kamata Co., Ltd. as planned on January 5th, 2024. Sunsho Pharmaceutical Co., Ltd. committed to "being the best partner for everyone involved with Sunsho Pharmaceutical," is dedicated to improving global health through innovative development in health foods, pharmaceuticals, general foods, and general merchandise. This acquisition marks a significant milestone, positioning Kamata Co., Ltd. as a wholly owned subsidiary of Sunsho Pharmaceutical Co., Ltd. By combining the expertise and resources of Sunsho Pharmaceutical Co., Ltd. and Kamata Co., Ltd., the unified entity is poised to pioneer novel products and will continue to deliver the best products, services, and value-added solutions to our valued customers.

BERLIN, Conn., Aug. 1, 2022 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®). This product was developed in collaboration with Natco Pharma Limited. Breckenridge received final approval for the 60mg/1.5mL (40mg/mL) strength. Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time. According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022. About Breckenridge: Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we strive to impact the health of the patients we and our customers serve. About Natco: Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals. For further information, please contact: Breckenridge Pharmaceutical, Inc. Robert Gasparino, Associate Vice President – Business Development Tel: 860-828-8140 E-mail: [email protected] *All brand names and trademarks are the property of their respective owners. SOURCE Breckenridge Pharmaceutical, Inc.

Tokyo, Japan, December 17, 2021 – CJP SP Holding, L.P., an investment fund operated and managed by global investment firm Carlyle (NASDAQ: CG), signed an agreement to sell 100% of its investment in Sunsho Pharmaceutical Co., Ltd (“Sunsho Pharmaceutical”), a contract manufacturing company of health & nutrition (“H&N”) and pharmaceutical products, to Towa Pharmaceutical Co., Ltd. (“Towa Pharmaceutical”), a company specializing in research and development, production, and marketing of generic drugs. The transaction is expected to be completed in February of 2022. Headquartered in Shizuoka, Sunsho Pharmaceutical is one of the largest contract manufacturers in Japan for soft capsules, seamless capsules, and other dosage forms for H&N and pharmaceutical use. The company focuses on producing absolute quality products and applies state-of-the-art contract manufacturing technology to create cutting-edge formulations and capsules. CJP SP Holding, L.P. acquired a 100% stake in Sunsho Pharmaceutical in August of 2014 through Carlyle’s third Japan buyout fund, Carlyle Japan Partners III, having recognized the company’s strong growth potential as a contract manufacturer in a steadily growing H&N market in Japan. Carlyle also saw the potential for value creation with Sunsho Pharmaceutical and within the H&N market in Japan by leveraging its local team knowledge, global platform strengths and deep experience in the healthcare and consumer sectors. Through Carlyle’s ownership, Sunsho Pharmaceutical strengthened its management structure and governance, initiated the launch of a new factory and research and development facility to enhance production capabilities, diversified its business portfolio to cater to new customers, and significantly increased its global revenues by bolstering and expanding its overseas business. Carlyle also worked closely with Sunsho Pharmaceutical’s management team to help drive innovation and co-create new value-add products and solutions with customers. Carlyle will transition full ownership to Towa Pharmaceutical to support Sunsho Pharmaceutical’s next phase of growth. Carlyle has made 31 investments in Japan since entering into the market in 2000 and this will be the 20th exit to date. Carlyle has a well-established history of investing in the healthcare sector, both in Japan and globally, investing more than US $14.7 billion of equity in over 80 deals in the global healthcare sector as of September 30, 2021. Healthcare investments in Japan include Qualicaps Co., Ltd., and Solasto Corporation.